The European Commission plans to request copies of patent settlements between brand-name drugmakers and generics companies as it continues an investigation into pay-for-delay agreements. "We will not take the view, per se, that patent settlements are probably illegal, but we would look closely at the justification the company gives for the settlement. We will look at the merits of the case," said Dominik Schnichels, head of the commission's drug task force.

Full Story:

Related Summaries